Psychiatr. praxi. 2022;23(3):153-159 | DOI: 10.36290/psy.2022.033

Mixed anxiety and depressive disorder: a review of the literature

MUDr. Eliška Bartečková, Ph.D., MUDr. Jana Hořínková, Ph.D., MUDr. Pavel Křenek
Psychiatrická klinika Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice Brno

Mixed anxiety and depressive disorder is a diagnostic category in the 10th and 11th editions of the International Classification of Diseases (ICD). It can be made when a patient shows co-occurring anxiety and depressive symptoms causing significant distress but not expressed in such severity that another anxiety or affective disorder can be diagnosed. Sometimes the existence of this disorder is questioned because of the low severity of symptoms, the difficulty of delineating it from similar conditions and the low diagnostic reliability. For example, it does not appear in the most recent fifth edition of the Diagnostic and Statistical Manual of Mental Disorders. However, in the context of the ICD, it is one of the most common psychiatric diagnoses, particularly in primary care. In the differential diagnosis, it is necessary first to exclude a possible physical cause of the disorder and then to rule out other situations where depressive and anxiety symptomatology may occur together, such as comorbid depressive and anxiety disorders. In pharmacological therapy, antidepressants from the group of selective serotonin reuptake inhibitors are primarily used. If unsuccessful, other agents with simultaneous efficacy on depressive and anxiety symptoms may be used. As adjuvant therapy, anxiolytics may be given for a limited time. Psychotherapy, particularly cognitive behavioural psychotherapy, is an essential therapeutic modality.

Keywords: mixed anxiety and depressive disorder, mixed depressive and anxiety disorder, subsyndromal anxiety, subsyndromal depression.

Accepted: October 11, 2022; Published: October 25, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bartečková E, Hořínková J, Křenek P. Mixed anxiety and depressive disorder: a review of the literature. Psychiatr. praxi. 2022;23(3):153-159. doi: 10.36290/psy.2022.033.
Download citation

References

  1. Kalin NH. The Critical Relationship Between Anxiety and Depression. Am J Psychiatry. 2020;177(5):365-7. Go to original source... Go to PubMed...
  2. Fawcett J, Cameron RP, Schatzberg AF. Mixed anxiety­‑depressive disorder: An undiagnosed and undertreated severity spectrum? In: Textbook of anxiety disorders, 2nd ed. Arlington, VA, US: American Psychiatric Publishing, Inc.; 2010. 241-57.
  3. Möller HJ, Bandelow B, Volz HP, Barnikol UB, Seifritz E, Kasper S. The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice. Eur Arch Psychiatry Clin Neurosci. 2016;266(8):725-36. Go to original source... Go to PubMed...
  4. Zinbarg RE, Barlow DH, Liebowitz M, Street L, Broadhead E, Katon W, et al. The DSM­‑IV field trial for mixed anxiety­‑depression. Am J Psychiatry. 1994;151(8):1153-62. Go to original source... Go to PubMed...
  5. Batelaan NM, Spijker J, de Graaf R, Cuijpers P. Mixed Anxiety Depression Should Not Be Included in DSM-5: J Nerv Ment, DiS. 2012;200(6):495-8. Go to original source... Go to PubMed...
  6. Praško J, Herman E, Hovorka J, Pašková B, Prašková H. Smíšená úzkostně depresivní porucha: příručka pro klinickou praxi. Praha: Galén; 2003.
  7. World Health Organization, editor. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization; 1993:248.
  8. American Psychiatric Association, editor. Diagnostic and statistical manual of mental disorders: DSM­‑IV; includes ICD-9-CM codes effective 1. Oct. 96. 4. ed., 7. print. Washington, DC; 1998:886.
  9. First MB. DSM-5 proposals for mood disorders: a cost-benefit analysis. Curr Opin Psychiatry. 2011;24(1):1-9. Go to original source... Go to PubMed...
  10. Regier DA, Narrow WE, Clarke DE, Kraemer HC, Kuramoto SJ, Kuhl EA, et al. DSM-5 Field Trials in the United States and Canada, Part II: Test­‑Retest Reliability of Selected Categorical Diagnoses. Am J Psychiatry. 2013;170(1):59-70. Go to original source... Go to PubMed...
  11. American Psychiatric Association, editor. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C: American Psychiatric Association; 2013:947. Go to original source...
  12. World Health Organization. ICD-11 [Internet]. Available from: https://icd.who.int/en.
  13. Mulder R. Trying to describe mixed anxiety and depression: Have we lost our way? Depress Anxiety. 2019;36:1122-4. Go to original source... Go to PubMed...
  14. Shevlin M, Hyland P, Nolan E, Owczarek M, Ben-Ezra M, Karatzias T. ICD-11 'mixed depressive and anxiety disorder' is clinical rather than sub-clinical and more common than anxiety and depression in the general population. Br J Clin Psychol. 2022;61(1):18-36. Go to original source... Go to PubMed...
  15. Walters K, Buszewicz M, Weich S, King M. Mixed anxiety and depressive disorder outcomes: prospective cohort study in primary care. Br J Psychiatry. 2011;198(6):472-8. Go to original source... Go to PubMed...
  16. Hettema JM, Aggen SH, Kubarych TS, Neale MC, Kendler KS. Identification and validation of mixed anxiety­‑depression. Psychol Med. 2015;45(14):3075-84. Go to original source... Go to PubMed...
  17. World Health Organization, editor. Diagnostic and management guidelines for mental disorders in primary care: ICD-10 chapter V, primary care version. Seattle: Hogrefe & Huber Publishers; 1996:95.
  18. Hranov LG. Comorbid anxiety and depression: illumination of a controversy. Int J Psychiatry Clin Pract. 2007;11(3):171-89. Go to original source... Go to PubMed...
  19. Malyszczak K, Pawlowski T. Distress and functioning in mixed anxiety and depressive disorder. Psychiatry Clin Neurosci. 2006;60(2):168-73. Go to original source... Go to PubMed...
  20. Preskorn SH, Fast GA. Beyond signs and symptoms: the case against a mixed anxiety and depression category. J Clin Psychiatry. 1993;54 Suppl:24-32.
  21. Braam AW, Copeland JRM, Delespaul PAEG, Beekman ATF, Como A, Dewey M, et al. Depression, subthreshold depression and comorbid anxiety symptoms in older Europeans: Results from the EURODEP concerted action. J Affect Disord. 2014;155:266-72. Go to original source... Go to PubMed...
  22. Fava M, Alpert JE, Carmin CN, Wisniewski SR, Trivedi MH, Biggs MM, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med. 2004;34(7):1299-308. Go to original source... Go to PubMed...
  23. Das­‑Munshi J, Goldberg D, Bebbington PE, Bhugra DK, Brugha TS, Dewey ME, et al. Public health significance of mixed anxiety and depression: beyond current classification. Br J Psychiatry. 2008;192(3):171-7. Go to original source... Go to PubMed...
  24. Haller H, Cramer H, Lauche R, Gass F, Dobos GJ. The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review. BMC Psychiatry. 2014;14(1):128. Go to original source... Go to PubMed...
  25. Lewinsohn PM, Shankman SA, Gau JM, Klein DN. The prevalence and co­‑morbidity of subthreshold psychiatric conditions. Psychol Med. 2004;34(4):613-22. Go to original source... Go to PubMed...
  26. Weisberg RB, Maki KM, Culpepper L, Keller MB. Is anyone reall, M.A.D.?: the occurrence and course of mixed anxiety­‑depressive disorder in a sample of primary care patients. J Nerv Ment, DiS. 2005;193(4):223-30. Go to original source... Go to PubMed...
  27. Barkow K, Heun R, Wittchen HU, Bedirhan Üstün T, Gänsicke M, Maier W. Mixed anxiety-depression in a 1 year follow­‑up study: shift to other diagnoses or remission? J Affect Disord. 2004;79(1-3):235-9. Go to original source... Go to PubMed...
  28. Egle UT, Heim C, Strauß B, Känel R von, editors. Psychosomatik - neurobiologisch fundiert und evidenzbasiert: ein Lehr- und Handbuch. 1. Auflage. Stuttgart: Verlag W. Kohlhammer; 2020:860. (Medizin).
  29. Schmidt NB, Kotov R, Bernstein A, Zvolensky MJ, Joiner TE, Lewinsohn PM. Mixed anxiety depression: Taxometric exploration of the validity of a diagnostic category in youth. J Affect Disord. 2007;98(1-2):83-9. Go to original source... Go to PubMed...
  30. Singleton N, Bumpstead R, O'Brien M, Lee A, Meltzer H. Psychiatric morbidity among adults living in private households, 2000. Int Rev Psychiatry Abingdon Engl. 2003;15(1-2):65-73. Go to original source... Go to PubMed...
  31. Liebowitz MR. Mixed anxiety and depression: should it be included in DSM­‑IV? J Clin Psychiatry. 1993;54 Suppl:4-7; discussion 17-20.Další literatura u autorky a na www.psychiatriepropraxi.cz
  32. Balestrieri M, Isola M, Quartaroli M, Roncolato M, Bellantuono C. Assessing mixed anxiety­‑depressive disorder. A national primary care survey. Psychiatry Res. 2010 Apr;176(2-3):197-201. Go to original source... Go to PubMed...
  33. Spijker J, Batelaan N, de Graaf R, Cuijpers P. Who is MADD? Mixed anxiety depressive disorder in the general population. J Affect Disord. 2010 Feb;121(1-2):180-3. Go to original source... Go to PubMed...
  34. Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol. 1991 Aug;100(3):316-36. Go to original source... Go to PubMed...
  35. Hettema JM. What is the genetic relationship between anxiety and depression? Am J Med Genet C Semin Med Genet. 2008 May 15;148C(2):140-6. Go to original source... Go to PubMed...
  36. Hettema JM, Neale MC, Myers JM, Prescott CA, Kendler KS. A population­‑based twin study of the relationship between neuroticism and internalizing disorders. Am J Psychiatry. 2006 May;163(5):857-64. Go to original source... Go to PubMed...
  37. Kunik ME. Surprisingly High Prevalence of Anxiety and Depression in Chronic Breathing Disorders*. CHEST J. 2005 Apr 1;127(4):1205. Go to original source... Go to PubMed...
  38. Albert PR, Vahid­‑Ansari F, Luckhart C. Serotonin­‑prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post­‑synaptic 5-HT1A receptor expression. Front Behav Neurosci. 2014;8:199. Go to original source... Go to PubMed...
  39. Tafet GE, Nemeroff CB. Pharmacological Treatment of Anxiety Disorders: The Role of the HPA Axis. Front Psychiatry. 2020 May 15;11:443. Go to original source... Go to PubMed...
  40. Gilbert K, Mineka S, Zinbarg RE, Craske MG, Adam EK. Emotion Regulation Regulates More Than Emotion: Associations of Momentary Emotion Regulation With Diurnal Cortisol in Current and Past Depression and Anxiety. Clin Psychol Sci. 2017 Jan;5(1):37-51. Go to original source... Go to PubMed...
  41. Ferrari F, Villa RF. The Neurobiology of Depression: an Integrated Overview from Biological Theories to Clinical Evidence. Mol Neurobiol. 2017 Sep;54(7):4847-65. Go to original source... Go to PubMed...
  42. Kovner R, Oler JA, Kalin NH. Cortico­‑Limbic Interactions Mediate Adaptive and Maladaptive Responses Relevant to Psychopathology. Am J Psychiatry. 2019 Dec 1;176(12):987-99. Go to original source... Go to PubMed...
  43. Praško J, Prašková H. Smíšená úzkostně depresivní porucha. In: Seifertová D, Praško J, Horáček J, Höschl C, editors. Postupy v léčbě psychických poruch. 2. revidované vydání. Praha: Academia Medica Pragensis; 2008. p. 287-300.
  44. Kasper S, Müller WE, Volz HP, Möller HJ, Koch E, Dienel A. Silexan in anxiety disorders: Clinical data and pharmacological background. World J Biol Psychiatry. 2018 Aug 18;19(6):412-20. Go to original source... Go to PubMed...
  45. Carrasco JL, Díaz­‑Marsá M, Sáiz­‑Ruiz J. Sertraline in the treatment of mixed anxiety and depression disorder. J Affect Disord. 2000 Jul;59(1):67-9. Go to original source... Go to PubMed...
  46. Khoonsari H, Oghazian MB, Kargar M, Moin M, Khalili H, Alimadadi A, et al. Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety­‑Depressive Disorder. Iran J Psychiatry Behav Sci. 2015 Jun;9(2):e230. Go to original source... Go to PubMed...
  47. Mohammad Reza Abbasi­‑Asl, Abbas Alimadadi, Hasan Khoonsari, Hossein Khalili, Padideh Ghaeli, Mohammad Sanatti, et al. Efficacy of an Eight Week Trial of Imipramine and Citalopram in Patients with Mixed Anxiety­‑Depressive Disorder. Iran J Psychiatry [Internet]. 2008 [cited 2022 May 1];3(4). Available from: https://ijps.tums.ac.ir/index.php/ijps/article/view/487.
  48. Rausch JL, Hobby HM, Shendarkar N, Johnson ME, Li J. Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis. J Clin Psychopharmacol. 2001 Apr;21(2):139-42. Go to original source... Go to PubMed...
  49. Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, et al. Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam Med J. 2016;52(3):159. Go to original source... Go to PubMed...
  50. Státní ústav pro kontrolu léčiv. Souhrn údajů o přípravku, Fluanxol 1 mg potahované tablety [Internet]. 2021 [cited 2022 May 19]. Available from: https://www.sukl.cz/modules/medication/download.php?file=SPC173178.pdf & type=spc & as=fluanxol­‑spc.
  51. Maneeton N, Maneeton B, Woottiluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta­‑analysis of randomized controlled trials. Drug Des Devel Ther. 2016 Jan;259. Go to original source... Go to PubMed...
  52. Hýža M. Pregabalin v léčbě generalizované úzkostné poruchy. Psychiatr Praxi. 2017;18(2):78-80. Go to original source...
  53. Olivares JM, Álvarez E, Carrasco JL, Pérez Páramo M, López­‑Gómez V. Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms: Int Clin Psychopharmacol. 2015 Sep;30(5):265-71. Go to original source... Go to PubMed...
  54. Tibrewal P, Looi JCL, Allison S, Bastiampillai T. Benzodiazepines for the long­‑term treatment of anxiety disorders? The Lancet. 2021 Jul;398(10295):119-20. Go to original source... Go to PubMed...
  55. Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. Depress Anxiety. 2018 Jun;35(6):502-14. Go to original source... Go to PubMed...
  56. Cuijpers P, Berking M, Andersson G, Quigley L, Kleiboer A, Dobson KS. A Meta­‑Analysis of Cognitive­‑Behavioural Therapy for Adult Depression, Alone and in Comparison with other Treatments. Can J Psychiatry. 2013 Jul;58(7):376-85. Go to original source... Go to PubMed...
  57. Echeburúa E, Salaberría K, de Corral P, Cenea R, Berasategui T. Treatment of Mixed Anxiety­‑Depression Disorder: Long­‑Term Outcome. Behav Cogn Psychother. 2006 Jan;34(1):95-101. Go to original source...
  58. Shafran R, Wroe A, Nagra S, Pissaridou E, Coughtrey A. Cognitive behaviour treatment of co­‑occurring depression and generalised anxiety in routine clinical practice. Branchi I, editor. PLOS ONE. 2018 Jul 26;13(7):e0201226. Go to original source... Go to PubMed...
  59. Cosci F, Fava GA. When Anxiety and Depression Coexist: The Role of Differential Diagnosis Using Clinimetric Criteria. Psychother Psychosom. 2021;90(5):308-17. Go to original source... Go to PubMed...
  60. ÚZIS Č. MKN-10 klasifikace [Internet]. mkn10.cz. 2022 [cited 2022 May 3]. Available from: https://mkn10.uzis.cz/




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.